Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease
- 1 December 2011
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 19 (5) , 1663-1669
Abstract
Patients with locally unresectable pancreatic cancer (AJCC stage III) have a median survival of 10–14 months. The objective of this study waKeywords
This publication has 19 references indexed in Scilit:
- NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancerSurgery, 2010
- A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic CancerAnnals of Surgical Oncology, 2009
- Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreasBritish Journal of Surgery, 2009
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of DiseaseJournal of the American College of Surgeons, 2008
- Validation of the 6th edition AJCC pancreatic cancer staging systemCancer, 2007
- 1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution ExperienceJournal of Gastrointestinal Surgery, 2006
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative TherapyAnnals of Surgical Oncology, 2006
- Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the PancreasAnnals of Surgery, 2004
- Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamoleJournal of Gastrointestinal Surgery, 1998
- Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal regionJournal of Surgical Oncology, 1989